Evidence map›Paper›PMID 42200433›Full record

ArticleACS chemical neuroscience2026

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-

Grant C Glatfelter, Serena S Schalk, Donna Walther, Alexander D Maitland, Nicholas R Gonzalez, John S Partilla, Nicholas A Anas, Andrew R Chadeayne, Marilyn Naeem, David R Manke and 2 more

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Syntheses and structures of two norpsilocin derivatives:Acta crystallographica. Section E, Crystallographic communications · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Grant C GlatfelterDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.ORCID 0000-0003-1011-9083
Serena S SchalkDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
Donna WaltherDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.
Alexander D MaitlandDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.
Nicholas R GonzalezDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.
John S PartillaDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.
Nicholas A AnasCaaMTech, Inc., Issaquah, Washington 98027, United States.
Andrew R ChadeayneCaaMTech, Inc., Issaquah, Washington 98027, United States.
Marilyn NaeemDepartment of Chemistry & Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.
David R MankeDepartment of Chemistry & Biochemistry, University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States.ORCID 0000-0002-2513-4801
John D McCorvyDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.ORCID 0000-0001-7555-9413
Michael H BaumannDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland 21224, United States.ORCID 0000-0001-7758-1470

Funding

Preclinical medication development for stimulant use disorderZIADA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$8.9M
Molecular Mechanisms of G protein-coupled Receptor Biased SignalingR35GM133421 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2019 to 2026
$3.3M
Structure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic PotentialR01MH133849 · NIMH · MEDICAL COLLEGE OF WISCONSIN · PI John D McCorvy · 2023 to 2026
$2.1M
Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorderR01DA061433 · NIDA · MEDICAL COLLEGE OF WISCONSIN · PI ADAM L. Halberstadt, John D McCorvy · 2024 to 2026
$1.5M
Intramural NIH HHS ZIA DA000522NIDA NIH HHS R01 DA061433NIGMS NIH HHS R35 GM133421NIMH NIH HHS R01 MH133849
6 · The paper itself

Abstract

Tryptamine psychedelics induce psychoactive effects via agonist actions at serotonin 2A receptors (5-HT

Indexed as

HallucinogensSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport ProteinsTryptaminesAnimalsDose-Response Relationship, DrugHead MovementsHumansMaleMiceMice, Inbred C57BLReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsHallucinogensReceptor, Serotonin, 5-HT2ASelective Serotonin Reuptake InhibitorsSerotonin 5-HT2 Receptor AgonistsSerotonin Plasma Membrane Transport ProteinsTryptamines4-MeO-MiPT5-HT2Ahead twitch responsemicepsychedelicsSERT

Identifiers

PMID42200433
PMCPMC13281393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.